

Phase II Dog Cancer Trial Commences

- * **GMP monepantel tablets arrive safely to veterinarians for commencement of Phase II trial**
- * **Recruitment and testing of monepantel (MPL) commencing in dogs with B cell lymphoma**
- * **Agreements underway with additional veterinary sites to accelerate recruitment**

9 September 2019 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce the safe arrival of its GMP grade monepantel tablets with veterinarians, now set to commence the Phase II anti-cancer trial in dogs. The trial will formally determine activity in pet owners' dogs with treatment naïve B cell lymphoma employing the new palatable and high dose tablet form of MPL. This newly developed tablet was optimized in the first half of this year to enable the dosing of pet dogs by their owners and to produce a formulation that could be commercialized.

The recruitment and treatment of pet owners' dogs with naïve B cell lymphoma has been selected as the initial target cancer, as it is hoped to further verify the success observed in treating canine lymphoma with MPL in our earlier short-term clinical study with the poorly palatable liquid formulation. Furthermore, lymphoma is one of the most common canine cancers and as such recruitment should be easier.

The new palatable tablet will enable these studies to be of longer duration, permitting the determination of efficacy over prolonged periods of time. With success in this first stage, PharmAust then plans to broaden the trial base to test for low dose maintenance of progression free survival and efficacy in other cancers.

PharmAust is expanding the recruitment to further sites in Australia in order to accelerate accrual rates and enable faster trial endpoint determination. Finalisation of agreements with these other sites is anticipated this and next month.

PharmAust's Chief Scientific Officer Dr Richard Mollard commented, "PharmAust is excited to restart the canine trials formally testing the anti-cancer activity of monepantel in dogs with treatment naïve lymphoma. PharmAust is looking forward to updating shareholders with the outcomes from these trials as the data become available."

Enquiries:

Dr Roger Aston
Executive Chairman & CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. PAA's subsidiary, Epichem, is a successful contract medicinal chemistry company that is forecasting \$4.2m revenues in FY2019/20.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs; was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials.